Funding and independence: who pays for this site
In short
About 4 minutes for the short version; 6 with every detail open.
- This site sells nothing. It shows no ads and has no sponsors.
- It takes no money from drug makers, sellers or clinics.
- At launch, the editor pays the costs. Any future grant will be listed here, with the amount.
- There are no ads and no ad cookies. Our host keeps visit statistics for us.
Each section starts with the short answer. The rest is folded under “In detail”.
What we do not take
Does anyone pay you to write this?
| This site | |
|---|---|
| Sells anything: products, tests, courses or consultations? | No Nothing is for sale here. |
| Takes money from drug makers, peptide sellers or clinics? | No Never, in any form. |
| Shows advertising? | No No ads of any kind. |
| Earns money from links, or from sending readers to someone? | No No paid links, no referral fees, no codes that give money off. |
| Has sponsors? | No No sponsors and no paid partners. |
| Tells you where to get a product? | No We name no sellers and link to none. |
We link only to sites on a fixed list. It holds regulators, law databases, PubMed and science journals, universities, anti-doping bodies, patient and harm-reduction groups, and a few non-profit services, such as the archive our photos come from. No one who sells medicines or peptides can be on it. A check runs every time the site is built. It stops the build if a page links anywhere else.
Why it has to be this way
Why so strict?
- Advertising is defined by its aim. Dutch law counts any attempt to get people to prescribe, supply or use a medicine.1
- No licence, no advertising. Any advertising for a medicine without a licence is forbidden. So is public advertising for prescription-only medicines.2,3
- An independent writer can still be advertising. The EU Court of Justice ruled that what counts is the purpose of the message.4
- So we earn nothing from any product. Without money from sales, our information stays information.
Many peptides on this site, such as BPC-157, have no licence as a medicine in the EU.5,6 If we earned money when someone bought one, our explanations could become advertising. Our page on Dutch law explains this in more detail.
In detail: The second reason: money shapes what people write , about 1 minute to read
The law is not the only reason. Money changes which questions get asked and how answers are framed, even when everyone means well.
A Cochrane review looked at 75 papers that compared studies paid for by a drug or device maker with studies paid for by others. The maker’s studies more often reported results and conclusions that favoured the product. By the usual quality checks they were not worse designed. On one check, blinding, they did better. The authors concluded there is an “industry bias” that the usual quality checks cannot explain.7
Some of what is said about these peptides comes from people who earn money from them: sellers, clinics and paid promoters. That does not make it false. But a source that earns money when you buy has a reason to stress benefits and play down risks. We want to be one source with no such reason. That is also why our editorial policy records who paid for the research we describe.
How the site is paid for
Then who pays?
| Source of money | Accepted? | What we publish |
|---|---|---|
| The editor’s own money | Yes, at launch | That the editor pays the costs |
| A grant from a public body or a charity | Possibly in future | The funder and the amount, on this page |
| Donations from readers | Only if we ever ask | The total, on this page; donors get nothing in return |
| Drug makers, peptide sellers, clinics, affiliate schemes | Never | Not applicable |
At launch, the site has no income at all. The editor pays for hosting and tools. A funder would get no say in what we write, and no early look at any page. If that ever changes, this page will say so first.
Your privacy
Do you track me?
| What you might expect | What happens here |
|---|---|
| Cookies | Three short-lived cookies from our host: against bots, for its own routing, and to group your page views into one visit. No ad cookies |
| Analytics or tracking scripts | Our host adds statistics scripts to every page. We see only totals, never who you are |
| Ads, social media buttons or videos from other sites | None |
| Fonts and images from other servers | None: we serve every file ourselves |
| What you type in the search box | Searched in your browser. It appears in the page address, so it can reach your browser history and our host’s statistics |
| Your choice of light or dark display | Kept in your own browser, only if you choose one |
Dutch law says a website must ask before it stores or reads anything on your device. There are exceptions for what is strictly needed to give you the service you asked for, and for statistics with little or no effect on your privacy.8 Below is everything that is stored, and why.
In detail: The details , about 2 minutes to read
- Display choice. If you switch between light and dark, your browser remembers that choice on your own device. It is never sent to us. If you never switch, nothing is stored.
- Security cookie. Our host, Lovable, runs on Cloudflare. Cloudflare sets one cookie, called __cf_bm, to tell people from automated bots. It expires after 30 minutes. We cannot read it and do not use it.
- Routing cookie. Our host sets a cookie called __dpl, so that every page you open comes from the same version of the site. It expires after 24 hours.
- Visit statistics. Our host adds small statistics scripts to every page. They record the page address, the website you came from, your browser and type of device, your language, an estimated country, clicks, how long you stay, and how fast the page loads. A cookie called session-id groups your page views into one visit; it expires after 30 minutes. The data goes to our host. We see only totals in its dashboard. We add no analytics of our own and build no profiles of readers.
- Server requests. Like every website, the server that sends you a page needs your device’s internet address to deliver it.
- No other websites. Every file a page loads comes from this site’s own address. Links to official sources open only when you choose to follow them.
- No accounts. You cannot log in, and we ask for no personal data.
Sources
Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.
In detail: All 8 sources, numbered as in the text , about 2 minutes to read
- (2007). Geneesmiddelenwet, artikel 1, eerste lid, onder hh, xx en ijij (invoeren, reclame, publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩
- (2007). Geneesmiddelenwet, artikelen 84 en 85 (reclame; publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩
- (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu (opens an external site) — accessed 20 October 2026 ↩
- (2009). Judgment of 2 April 2009, Criminal proceedings against Frede Damgaard, Case C-421/07. EUR-Lex (CELEX 62007CJ0421). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026 ↩
- (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026 ↩
- (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026 ↩
- (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2:MR000033. Review doi:10.1002/14651858.MR000033.pub3 (opens an external site) ↩
- (1998). Telecommunicatiewet, artikel 11.7a (opslaan van of toegang tot informatie in de randapparatuur van een gebruiker). wetten.overheid.nl (BWBR0009950), version in force from 15 August 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩